Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more
Halozyme Therapeutics Inc (HALO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.354x
Based on the latest financial reports, Halozyme Therapeutics Inc (HALO) has a cash flow conversion efficiency ratio of 0.354x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($178.60 Million) by net assets ($503.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Halozyme Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Halozyme Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Halozyme Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Halozyme Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Nhu Co Ltd
SHE:002001
|
0.075x |
|
Akbank T.A.S
F:AKB2
|
-0.212x |
|
WISE PLC LS -01
F:6WS
|
N/A |
|
Sunoco LP
NYSE:SUN
|
0.072x |
|
Falabella
SN:FALABELLA
|
0.018x |
|
Wynn Resorts Limited
NASDAQ:WYNN
|
-0.294x |
|
Xero Ltd
AU:XRO
|
0.132x |
|
Hudbay Minerals Inc.
NYSE:HBM
|
0.037x |
Annual Cash Flow Conversion Efficiency for Halozyme Therapeutics Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Halozyme Therapeutics Inc from 2001 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $363.82 Million | $479.06 Million | 1.317x | -71.60% |
| 2023-12-31 | $83.81 Million | $388.57 Million | 4.636x | +227.87% |
| 2022-12-31 | $169.80 Million | $240.11 Million | 1.414x | -6.99% |
| 2021-12-31 | $196.95 Million | $299.44 Million | 1.520x | +314.12% |
| 2020-12-31 | $151.05 Million | $55.45 Million | 0.367x | +139.44% |
| 2019-12-31 | $91.77 Million | $-85.42 Million | -0.931x | -368.05% |
| 2018-12-31 | $248.89 Million | $-49.50 Million | -0.199x | -130.91% |
| 2017-12-31 | $208.37 Million | $134.05 Million | 0.643x | -58.52% |
| 2016-12-31 | $-32.48 Million | $-50.38 Million | 1.551x | +279.86% |
| 2015-12-31 | $43.00 Million | $-37.08 Million | -0.862x | +24.95% |
| 2014-12-31 | $41.35 Million | $-47.52 Million | -1.149x | -146.56% |
| 2013-12-31 | $-19.99 Million | $-49.34 Million | 2.468x | +287.44% |
| 2012-12-31 | $48.85 Million | $-64.33 Million | -1.317x | +58.22% |
| 2011-12-31 | $10.90 Million | $-34.35 Million | -3.151x | -41.31% |
| 2010-12-31 | $20.35 Million | $-45.39 Million | -2.230x | +61.65% |
| 2009-12-31 | $6.90 Million | $-40.15 Million | -5.816x | -152.86% |
| 2008-12-31 | $15.38 Million | $-35.37 Million | -2.300x | -89880.87% |
| 2007-12-31 | $57.77 Million | $-147.66K | -0.003x | -100.83% |
| 2006-12-31 | $23.08 Million | $7.08 Million | 0.307x | +142.97% |
| 2005-12-31 | $18.21 Million | $-13.00 Million | -0.714x | -37.11% |
| 2004-12-31 | $14.82 Million | $-7.72 Million | -0.521x | +89.46% |
| 2003-12-31 | $10.06K | $-49.73K | -4.942x | -669.13% |
| 2002-12-31 | $86.81K | $-55.78K | -0.642x | +57.31% |
| 2001-12-31 | $22.84K | $-34.37K | -1.505x | -- |